Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1982 2
1983 2
1984 1
1985 2
1987 7
1988 3
1989 3
1991 2
1992 2
1993 2
1994 3
1995 12
1996 7
1997 7
1998 10
1999 12
2000 17
2001 16
2002 5
2003 7
2004 4
2005 9
2006 5
2007 5
2008 6
2009 6
2010 2
2011 2
2012 6
2013 6
2014 1
2015 8
2016 6
2017 9
2018 9
2019 12
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

214 results
Results by year
Filters applied: . Clear all
Page 1
Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile.
Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, Gheesling LL, Carlone GM, Høiby EA, Holst J, Nøkleby H, Rosenqvist E, Sierra G, Campa C, Sotolongo F, Vega J, Garcia J, Herrera P, Poolman JT, Perkins BA. Tappero JW, et al. JAMA. 1999 Apr 28;281(16):1520-7. doi: 10.1001/jama.281.16.1520. JAMA. 1999. PMID: 10227322 Clinical Trial.
Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial.
Marshall HS, Richmond PC, Beeslaar J, Jiang Q, Jansen KU, Garcés-Sánchez M, Martinón-Torres F, Szenborn L, Wysocki J, Eiden J, Harris SL, Jones TR, Lee SS, Perez JL; 6108A12001 Study Investigators. Marshall HS, et al. Lancet Infect Dis. 2017 Jan;17(1):58-67. doi: 10.1016/S1473-3099(16)30314-0. Epub 2016 Oct 11. Lancet Infect Dis. 2017. PMID: 27745812 Clinical Trial.
Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.
de Moraes JC, Perkins BA, Camargo MC, Hidalgo NT, Barbosa HA, Sacchi CT, Landgraf IM, Gattas VL, Vasconcelos Hde G, et al. de Moraes JC, et al. Lancet. 1992 Oct 31;340(8827):1074-8. doi: 10.1016/0140-6736(92)93086-3. Lancet. 1992. PMID: 1357461
Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland.
Perkins BA, Jonsdottir K, Briem H, Griffiths E, Plikaytis BD, Hoiby EA, Rosenqvist E, Holst J, Nokleby H, Sotolongo F, Sierra G, Campa HC, Carlone GM, Williams D, Dykes J, Kapczynski D, Tikhomirov E, Wenger JD, Broome CV. Perkins BA, et al. J Infect Dis. 1998 Mar;177(3):683-91. doi: 10.1086/514232. J Infect Dis. 1998. PMID: 9498448 Clinical Trial.
Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease.
Boslego J, Garcia J, Cruz C, Zollinger W, Brandt B, Ruiz S, Martinez M, Arthur J, Underwood P, Silva W, et al. Boslego J, et al. Vaccine. 1995 Jun;13(9):821-9. doi: 10.1016/0264-410x(94)00037-n. Vaccine. 1995. PMID: 7483804 Clinical Trial.
214 results
Jump to page
Feedback